{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:16:03Z","timestamp":1791483363194,"version":"4.3.4"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/nrcardio.2016.98","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T11:18:46Z","timestamp":1468495126000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy"],"prefix":"10.1038","volume":"13","author":[{"given":"Julian O. M.","family":"Ormerod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Frenneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark V.","family":"Sherrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"BFnrcardio201698_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","volume":"6","author":"M Sherrid","year":"2013","unstructured":"Sherrid, M.  et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil. Circ. Heart Fail 6, 694\u2013702 (2013).","journal-title":"Circ. Heart Fail"},{"key":"BFnrcardio201698_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/hrt.2010.217182","volume":"98","author":"C O'Mahony","year":"2012","unstructured":"O'Mahony, C.  et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 98, 116\u2013125 (2012).","journal-title":"Heart"},{"key":"BFnrcardio201698_CR3","first-page":"405","volume":"298","author":"BJ Maron","year":"2007","unstructured":"Maron, B. J.  et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298, 405\u2013412 (2007).","journal-title":"JAMA"},{"key":"BFnrcardio201698_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","volume":"62","author":"AA Geisterfer-Lowrance","year":"1990","unstructured":"Geisterfer-Lowrance, A. A.  et al. A molecular basis for familial hypertrophic cardiomyopathy: a \u03b2 cardiac myosin heavy chain gene missense mutation. Cell 62, 999\u20131006 (1990).","journal-title":"Cell"},{"key":"BFnrcardio201698_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0092-8674(94)90054-X","volume":"77","author":"L Thierfelder","year":"1994","unstructured":"Thierfelder, L.  et al. \u03b1-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77, 701\u2013712 (1994).","journal-title":"Cell"},{"key":"BFnrcardio201698_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/CIRCRESAHA.109.202440","volume":"105","author":"S Marston","year":"2009","unstructured":"Marston, S.  et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ. Res. 105, 219\u2013222 (2009).","journal-title":"Circ. Res."},{"key":"BFnrcardio201698_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1161\/CIRCHEARTFAILURE.111.963702","volume":"5","author":"SJ van Dijk","year":"2012","unstructured":"van Dijk, S. J.  et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ. Heart Fail. 5, 36\u201346 (2012).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio201698_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12265-009-9131-8","volume":"2","author":"C Ferrantini","year":"2009","unstructured":"Ferrantini, C.  et al. Mechanical and energetic consequences of HCM-causing mutations. J. Cardiovasc. Transl. Res. 2, 441\u2013451 (2009).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"BFnrcardio201698_CR9","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1113\/jphysiol.2014.274571","volume":"592","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends, E. R.  et al. Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation. J. Physiol. 592, 3257\u20133272 (2014).","journal-title":"J. Physiol."},{"key":"BFnrcardio201698_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0008-6363(99)00213-8","volume":"44","author":"CS Redwood","year":"1999","unstructured":"Redwood, C. S.  et al. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc. Res. 44, 20\u201336 (1999).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201698_CR11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","volume":"356","author":"S Neubauer","year":"2007","unstructured":"Neubauer, S. The failing heart \u2014 an engine out of fuel. N. Engl. J. Med. 356, 1140\u20131151 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201698_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","volume":"19","author":"H Ashrafian","year":"2003","unstructured":"Ashrafian, H.  et al. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 19, 263\u2013268 (2003).","journal-title":"Trends Genet."},{"key":"BFnrcardio201698_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","volume":"41","author":"JG Crilley","year":"2003","unstructured":"Crilley, J. G.  et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41, 1776\u20131782 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201698_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cvr\/cvu127","volume":"103","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends, E. R.  et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc. Res. 103, 248\u2013257 (2014).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201698_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1161\/CIRCRESAHA.111.242974","volume":"109","author":"H Ashrafian","year":"2011","unstructured":"Ashrafian, H.  et al. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ. Res. 109, 86\u201396 (2011).","journal-title":"Circ. Res."},{"key":"BFnrcardio201698_CR16","volume-title":"Metabolic Syndrome and Cardiovascular Disease","author":"TB Levine","year":"2013","unstructured":"Levine, T. B. & Levine, A. B. Metabolic Syndrome and Cardiovascular Disease 2nd ed (Wiley-Blackwell, 2013)."},{"key":"BFnrcardio201698_CR17","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1161\/01.CIR.97.25.2536","volume":"97","author":"WI Jung","year":"1998","unstructured":"Jung, W. I.  et al. 31PNMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97, 2536\u20132542 (1998).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCGENETICS.114.000221","volume":"7","author":"S Singh","year":"2014","unstructured":"Singh, S.  et al. Cardiac energetic impairment in heart disease and the potential role of metabolic modulators: a review for clinicians. Circ. Cardiovasc. Genet. 7, 720\u2013728 (2014).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"BFnrcardio201698_CR19","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1161\/01.CIR.96.7.2190","volume":"96","author":"S Neubauer","year":"1997","unstructured":"Neubauer, S.  et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96, 2190\u20132196 (1997).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00259-009-1350-3","volume":"37","author":"SA Timmer","year":"2010","unstructured":"Timmer, S. A.  et al. Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy. Eur. J. Nucl. Med. Mol. Imaging 37, 779\u2013788 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrcardio201698_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0002-8703(97)70143-1","volume":"133","author":"S Ishiwata","year":"1997","unstructured":"Ishiwata, S.  et al. Mechanical efficiency in hypertrophic cardiomyopathy assessed by positron emission tomography with carbon 11 acetate. Am. Heart J. 133, 497\u2013503 (1997).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201698_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ehjci\/jes242","volume":"14","author":"SA Timmer","year":"2013","unstructured":"Timmer, S. A. & Knaapen, P. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography. Eur. Heart J. Cardiovasc. Imaging 14, 95\u2013101 (2013).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"BFnrcardio201698_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/hmg\/10.11.1215","volume":"10","author":"E Blair","year":"2001","unstructured":"Blair, E.  et al. Mutations in the \u03b32 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10, 1215\u20131220 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrcardio201698_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1113\/jphysiol.2006.108944","volume":"574","author":"DG Hardie","year":"2006","unstructured":"Hardie, D. G.  et al. AMP-activated protein kinase \u2014 development of the energy sensor concept. J. Physiol. 574, 7\u201315 (2006).","journal-title":"J. Physiol."},{"key":"BFnrcardio201698_CR25","first-page":"437","volume":"55","author":"F Merante","year":"1994","unstructured":"Merante, F.  et al. Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA(glycine) gene. Am. J. Hum. Genet. 55, 437\u2013446 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrcardio201698_CR26","doi-asserted-by":"publisher","first-page":"H575","DOI":"10.1152\/ajpheart.00619.2002","volume":"284","author":"DT Lucas","year":"2003","unstructured":"Lucas, D. T.  et al. Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 284, H575\u2013H583 (2003).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio201698_CR27","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/eurheartj\/ehp184","volume":"30","author":"K Unno","year":"2009","unstructured":"Unno, K.  et al. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur. Heart J. 30, 1853\u20131862 (2009).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201698_CR28","doi-asserted-by":"publisher","first-page":"11492","DOI":"10.1073\/pnas.96.20.11492","volume":"96","author":"R Lodi","year":"1999","unstructured":"Lodi, R.  et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 96, 11492\u201311495 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio201698_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0008-6363(01)00357-1","volume":"52","author":"R Lodi","year":"2001","unstructured":"Lodi, R.  et al. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo31P magnetic resonance spectroscopy study. Cardiovasc. Res. 52, 111\u2013119 (2001).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201698_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.10419","volume":"53","author":"M Bunse","year":"2003","unstructured":"Bunse, M.  et al. Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia. Ann. Neurol. 53, 121\u2013123 (2003).","journal-title":"Ann. Neurol."},{"key":"BFnrcardio201698_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.stem.2012.10.010","volume":"12","author":"F Lan","year":"2013","unstructured":"Lan, F.  et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101\u2013113 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnrcardio201698_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.yjmcc.2010.06.006","volume":"49","author":"AC Hoskins","year":"2010","unstructured":"Hoskins, A. C.  et al. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 49, 737\u2013745 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"BFnrcardio201698_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/heart.87.3.247","volume":"87","author":"Y Matsumura","year":"2002","unstructured":"Matsumura, Y.  et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart 87, 247\u2013251 (2002).","journal-title":"Heart"},{"key":"BFnrcardio201698_CR34","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1172\/JCI1940","volume":"101","author":"M Spindler","year":"1998","unstructured":"Spindler, M.  et al. Diastolic dysfunction and altered energetics in the \u03b1MHC403\/+ mouse model of familial hypertrophic cardiomyopathy. J. Clin. Invest. 101, 1775\u20131783 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio201698_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1172\/JCI15967","volume":"112","author":"MM Javadpour","year":"2003","unstructured":"Javadpour, M. M.  et al. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J. Clin. Invest. 112, 768\u2013775 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio201698_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1442-200X.1996.tb03496.x","volume":"38","author":"N G\u00fcnal","year":"1996","unstructured":"G\u00fcnal, N.  et al. Heart disease in Friedreich's ataxia: a clinical and echocardiographic study. Acta Paediatr. Jpn 38, 308\u2013311 (1996).","journal-title":"Acta Paediatr. Jpn"},{"key":"BFnrcardio201698_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0002-9343(87)90369-X","volume":"82","author":"DV Unverferth","year":"1987","unstructured":"Unverferth, D. V.  et al. Morphologic and functional characteristics of the heart in Friedreich's ataxia. Am. J. Med. 82, 5\u201310 (1987).","journal-title":"Am. J. Med."},{"key":"BFnrcardio201698_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCGENETICS.113.000324","volume":"7","author":"ML Alves","year":"2014","unstructured":"Alves, M. L.  et al. Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ. Cardiovasc. Genet. 7, 132\u2013143 (2014).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"BFnrcardio201698_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1161\/CIRCHEARTFAILURE.114.001585","volume":"8","author":"CW Tong","year":"2015","unstructured":"Tong, C. W.  et al. Phosphorylation of cardiac myosin-binding protein-C is a critical mediator of diastolic function. Circ. Heart Fail. 8, 582\u2013594 (2015).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio201698_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","volume":"127","author":"R Coppini","year":"2013","unstructured":"Coppini, R.  et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127, 575\u2013584 (2013).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.amjcard.2010.03.020","volume":"106","author":"I Olivotto","year":"2010","unstructured":"Olivotto, I.  et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am. J. Cardiol. 106, 261\u2013267 (2010).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201698_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ahj.2010.02.002","volume":"159","author":"K Abozguia","year":"2010","unstructured":"Abozguia, K.  et al. Left ventricular strain and untwist in hypertrophic cardiomyopathy: relation to exercise capacity. Am. Heart J. 159, 825\u2013832 (2010).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201698_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2006.11.030","volume":"122","author":"F Pelliccia","year":"2007","unstructured":"Pelliccia, F.  et al. Cumulative exercise-induced left ventricular systolic and diastolic dysfunction in hypertrophic cardiomyopathy. Int. J. Cardiol. 122, 76\u201378 (2007).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201698_CR44","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1136\/hrt.2007.116970","volume":"94","author":"K Sakata","year":"2008","unstructured":"Sakata, K.  et al. Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes. Heart 94, 1282\u20131287 (2008).","journal-title":"Heart"},{"key":"BFnrcardio201698_CR45","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0735-1097(00)00818-4","volume":"36","author":"K Okeie","year":"2000","unstructured":"Okeie, K.  et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 36, 856\u2013863 (2000).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201698_CR46","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/eurheartj\/ehv120","volume":"36","author":"S Dass","year":"2015","unstructured":"Dass, S.  et al. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. Eur. Heart J. 36, 1547\u20131554 (2015).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201698_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0894-7317(97)70112-3","volume":"10","author":"MV Sherrid","year":"1997","unstructured":"Sherrid, M. V.  et al. Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy \u2014 the lobster claw abnormality. J. Am. Soc. Echocardiogr. 10, 707\u2013712 (1997).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"BFnrcardio201698_CR48","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jacc.2006.10.070","volume":"49","author":"I Barac","year":"2007","unstructured":"Barac, I.  et al. Effect of obstruction on longitudinal left ventricular shortening in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 49, 1203\u20131211 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201698_CR49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jacc.2009.03.052","volume":"54","author":"MV Sherrid","year":"2009","unstructured":"Sherrid, M. V.  et al. Reflections of inflections in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 54, 212\u2013219 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201698_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0735-1097(85)80244-8","volume":"6","author":"BJ Maron","year":"1985","unstructured":"Maron, B. J.  et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J. Am. Coll. Cardiol. 6, 1\u201318 (1985).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201698_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.echo.2003.12.012","volume":"17","author":"HM Conklin","year":"2004","unstructured":"Conklin, H. M.  et al. Biphasic left ventricular outflow and its mechanism in hypertrophic obstructive cardiomyopathy. J. Am. Soc. Echocardiogr. 17, 375\u2013383 (2004).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"BFnrcardio201698_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/hrt.2004.036103","volume":"91","author":"OA Breithardt","year":"2005","unstructured":"Breithardt, O. A.  et al. Mid systolic septal deceleration in hypertrophic cardiomyopathy: clinical value and insights into the pathophysiology of outflow tract obstruction by tissue Doppler echocardiography. Heart 91, 379\u2013380 (2005).","journal-title":"Heart"},{"key":"BFnrcardio201698_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0735-1097(85)80418-6","volume":"5","author":"J Ross","year":"1985","unstructured":"Ross, J. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J. Am. Coll. Cardiol. 5, 811\u2013826 (1985).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201698_CR54","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1148\/radiology.219.3.r01jn25637","volume":"219","author":"HP Beyerbacht","year":"2001","unstructured":"Beyerbacht, H. P.  et al. Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 219, 637\u2013643 (2001).","journal-title":"Radiology"},{"key":"BFnrcardio201698_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1532-429X-16-29","volume":"16","author":"M Mahmod","year":"2014","unstructured":"Mahmod, M.  et al. Myocardial perfusion and oxygenation are impaired during stress in severe aortic stenosis and correlate with impaired energetics and subclinical left ventricular dysfunction. J. Cardiovasc. Magn. Reson. 16, 29 (2014).","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"Suppl. I","key":"BFnrcardio201698_CR56","first-page":"A1","volume":"95","author":"H Ashrafian","year":"2009","unstructured":"Ashrafian, H.  et al. Aortic stenosis with impaired ventricular function manifests impaired cardiac metabolism: implications for prognosis and surgical intervention. Heart 95 (Suppl. I), A1\u2013A87 (2009).","journal-title":"Heart"},{"key":"BFnrcardio201698_CR57","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1161\/CIRCIMAGING.113.000559","volume":"6","author":"M Mahmod","year":"2013","unstructured":"Mahmod, M.  et al. Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosis. Circ. Cardiovasc. Imag. 6, 808\u2013816 (2013).","journal-title":"Circ. Cardiovasc. Imag."},{"key":"BFnrcardio201698_CR58","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1161\/01.CIR.92.10.2886","volume":"92","author":"SS Lele","year":"1995","unstructured":"Lele, S. S.  et al. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation. 92, 2886\u20132894 (1995).","journal-title":"Circulation."},{"key":"BFnrcardio201698_CR59","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/01.CIR.79.4.766","volume":"79","author":"RO3rd Cannon","year":"1989","unstructured":"Cannon, R. O. 3rd  et al. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation 79, 766\u2013775 (1989).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1161\/01.CIR.71.2.234","volume":"71","author":"RO3rd Cannon","year":"1985","unstructured":"Cannon, R. O. 3rd  et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 71, 234\u2013243 (1985).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR61","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/01.CIR.76.6.1214","volume":"76","author":"PT O'Gara","year":"1987","unstructured":"O'Gara, P. T.  et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 76, 1214\u20131223 (1987).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR62","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa025050","volume":"349","author":"F Cecchi","year":"2003","unstructured":"Cecchi, F.  et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N. Engl. J. Med. 349, 1027\u20131035 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201698_CR63","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/eurjhf\/hfr135","volume":"13","author":"SA Timmer","year":"2011","unstructured":"Timmer, S. A.  et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur. J. Heart Fail. 13, 1283\u20131289 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201698_CR64","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.echo.2015.08.015","volume":"28","author":"JR Po","year":"2015","unstructured":"Po, J. R.  et al. Doppler systolic signal void in hypertrophic cardiomyopathy: apical aneurysm, and severe obstruction without elevated intraventricular velocities. J. Am. Soc. Echocardiogr. 28, 1462\u20131473 (2015).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"BFnrcardio201698_CR65","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1540-8175.2009.00905.x","volume":"26","author":"A Shah","year":"2009","unstructured":"Shah, A.  et al. Severe symptoms in mid and apical hypertrophic cardiomyopathy. Echocardiography 26, 922\u2013933 (2009).","journal-title":"Echocardiography"},{"key":"BFnrcardio201698_CR66","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.108.781401","volume":"18","author":"MS Maron","year":"2008","unstructured":"Maron, M. S.  et al. Prevalence, clinical significance and natural history of left ventricular aneurysms in hypertrophic cardiomyopathy. Circulation 18, 1541\u20131549 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR67","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmg.2014.10.004","volume":"8","author":"DK Dawson","year":"2015","unstructured":"Dawson, D. K.  et al. Tako-tsubo cardiomyopathy: a heart stressed out of energy? JACC Cardiovasc. Imaging 8, 985\u2013987 (2015).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"BFnrcardio201698_CR68","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjcard.2015.01.541","volume":"115","author":"CJ Neil","year":"2015","unstructured":"Neil, C. J.  et al. Relation of delayed recovery of myocardial function after takotsubo cardiomyopathy to subsequent quality of life. Am. J. Cardiol. 115, 1085\u20131089 (2015).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201698_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/01.CIR.97.1.41","volume":"97","author":"MV Sherrid","year":"1998","unstructured":"Sherrid, M. V.  et al. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 97, 41\u201347 (1998).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR70","doi-asserted-by":"publisher","first-page":"E174","DOI":"10.1111\/j.1540-8175.2011.01459.x","volume":"28","author":"MV Sherrid","year":"2011","unstructured":"Sherrid, M. V.  et al. Reversal of acute systolic dysfunction and cardiogenic shock in hypertrophic cardiomyopathy by surgical relief of obstruction. Echocardiography. 28, E174\u2013E179 (2011).","journal-title":"Echocardiography."},{"key":"BFnrcardio201698_CR71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1161\/01.RES.38.3.172","volume":"38","author":"S Sasayama","year":"1976","unstructured":"Sasayama, S.  et al. Adaptations of the left ventricle to chronic pressure overload. Circ. Res. 38, 172\u2013178 (1976).","journal-title":"Circ. Res."},{"key":"BFnrcardio201698_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0033-0620(76)90021-9","volume":"18","author":"J Ross Jr.","year":"1976","unstructured":"Ross, J. Jr. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. Prog. Cardiovasc. Dis. 18, 255\u2013264 (1976).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"BFnrcardio201698_CR73","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/01.CIR.29.5.739","volume":"26","author":"J Ross Jr","year":"1964","unstructured":"Ross, J. Jr & Braunwald, E. The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. Circulation 26, 739\u2013749 (1964).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR74","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1067\/mje.2000.111010","volume":"13","author":"Y Mishiro","year":"2000","unstructured":"Mishiro, Y.  et al. Use of angiotensin II stress pulsed tissue Doppler imaging to evaluate regional left ventricular contractility in patients with hypertrophic cardiomyopathy. J. Am. Soc. Echocardiol. 13, 1065\u20131073 (2000).","journal-title":"J. Am. Soc. Echocardiol."},{"issue":"Suppl.","key":"BFnrcardio201698_CR75","first-page":"77","volume":"4","author":"J Ross Jr","year":"1976","unstructured":"Ross, J. Jr  et al. Preload, afterload, and the role of afterload mismatch in the descending limb of cardiac function. Eur. J. Cardiol. 4 (Suppl.), 77\u201386 (1976).","journal-title":"Eur. J. Cardiol."},{"key":"BFnrcardio201698_CR76","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1113\/jphysiol.2006.107557","volume":"575","author":"SG Sirenko","year":"2006","unstructured":"Sirenko, S. G.  et al. Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts \u2014 role of myofilament Ca2+ sensitivity increase. J. Physiol. 575, 201\u2013213 (2006).","journal-title":"J. Physiol."},{"key":"BFnrcardio201698_CR77","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1074\/jbc.M006745200","volume":"30","author":"BC Knollman","year":"2001","unstructured":"Knollman, B. C.  et al. Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J. Biol. Chem. 30, 10039\u201310048 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio201698_CR78","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.111.300436","volume":"112","author":"V Sequeira","year":"2013","unstructured":"Sequeira, V.  et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ. Res. 112, 1491\u20131505 (2013).","journal-title":"Circ. Res."},{"key":"BFnrcardio201698_CR79","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1161\/01.CIR.86.2.467","volume":"86","author":"RC Saumarez","year":"1992","unstructured":"Saumarez, R. C.  et al. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation 86, 467\u2013474 (1992).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR80","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/europace\/eur362","volume":"14","author":"C O'Mahony","year":"2012","unstructured":"O'Mahony, C.  et al. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace 14, 724\u2013733 (2012).","journal-title":"Europace"},{"key":"BFnrcardio201698_CR81","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1540-8167.2007.00780.x","volume":"18","author":"YM Cha","year":"2007","unstructured":"Cha, Y. M.  et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J. Cardiovasc. Electrophysiol. 18, 483\u2013487 (2007).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"BFnrcardio201698_CR82","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","volume":"130","author":"RH Chan","year":"2014","unstructured":"Chan, R. H.  et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130, 484\u2013495 (2014).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR83","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1056\/NEJM198903233201202","volume":"320","author":"JA Wagner","year":"1989","unstructured":"Wagner, J. A.  et al. Calcium-antagonist receptors in the atrial tissue of patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 320, 755\u2013761 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201698_CR84","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/01.CIR.79.4.836","volume":"79","author":"JE Brush Jr","year":"1989","unstructured":"Brush, J. E. Jr  et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79, 836\u2013844 (1989).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR85","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.yjmcc.2010.01.011","volume":"48","author":"S Huke","year":"2010","unstructured":"Huke, S. & Knollmann, B. C. Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. J. Mol. Cell. Cardiol. 48, 824\u2013833 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"BFnrcardio201698_CR86","first-page":"3893","volume":"118","author":"F Baudenbacher","year":"2008","unstructured":"Baudenbacher, F.  et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J. Clin. Invest. 118, 3893\u20133903 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio201698_CR87","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/CIRCRESAHA.113.301055","volume":"112","author":"S Huke","year":"2013","unstructured":"Huke, S.  et al. Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments. Circ. Res. 112, 1334\u20131344 (2013).","journal-title":"Circ. Res."},{"key":"BFnrcardio201698_CR88","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1096\/fj.07-8974com","volume":"22","author":"SB Danik","year":"2008","unstructured":"Danik, S. B.  et al. Electrical remodeling contributes to complex tachyarrhythmias in connexin43-deficient mouse hearts. FASEB J. 22, 1204\u20131212 (2008).","journal-title":"FASEB J."},{"key":"BFnrcardio201698_CR89","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra0902923","volume":"364","author":"H Watkins","year":"2011","unstructured":"Watkins, H.  et al. Inherited cardiomyopathies. N. Engl. J. Med. 364, 1643\u20131656 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201698_CR90","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green, E. M.  et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617\u2013621 (2016).","journal-title":"Science"},{"key":"BFnrcardio201698_CR91","doi-asserted-by":"publisher","first-page":"e002764","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","volume":"9","author":"I Olivotto","year":"2016","unstructured":"Olivotto, I.  et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. Circ. Heart Fail. 9, e002764 (2016).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio201698_CR92","unstructured":"US National Library of Science. ClinicalTrials.gov\n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02291237\n                    \n                   (2016)."},{"key":"BFnrcardio201698_CR93","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.pharmthera.2008.05.007","volume":"119","author":"JO Ormerod","year":"2008","unstructured":"Ormerod, J. O.  et al. Impaired energetics in heart failure \u2014 a new therapeutic target. Pharmacol. Ther. 119, 264\u2013274 (2008).","journal-title":"Pharmacol. Ther."},{"key":"BFnrcardio201698_CR94","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cvr\/cvv023","volume":"105","author":"J Tardiff","year":"2015","unstructured":"Tardiff, J.  et al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc. Res. 105, 457\u2013470 (2015).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201698_CR95","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia, K.  et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122, 1562\u20131569 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio201698_CR96","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1039\/C4MB00594E","volume":"11","author":"K Gehmlich","year":"2015","unstructured":"Gehmlich, K.  et al. Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. Mol. Biosyst. 11, 564\u2013573 (2015).","journal-title":"Mol. Biosyst."},{"key":"BFnrcardio201698_CR97","unstructured":"US National Library of Science. ClinicalTrials.gov\n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01696370\n                    \n                   (2013)."},{"key":"BFnrcardio201698_CR98","unstructured":"US National Library of Science. ClinicalTrials.gov\n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01721967\n                    \n                   (2016)."},{"key":"BFnrcardio201698_CR99","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","volume":"3","author":"CY Ho","year":"2015","unstructured":"Ho, C. Y.  et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 3, 180\u2013188 (2015).","journal-title":"JACC Heart Fail."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.98.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.98","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.98.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:59:27Z","timestamp":1684468767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2016.98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFnrcardio201698"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2016.98","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]},"assertion":[{"value":"14 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P.F. is the inventor of method of use patents for perhexiline in heart muscle diseases; these patents are owned by Heart Metabolics in which he has no financial interest. M.V.S. has provided protocol consultation to Heart Metabolics. J.O.M.O. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}